Study of the Role of Innate Lymphoid Cells and Natural Killer Cells in Immune Activation of Vitiligo - INNATE Vitiligo — INNATEvitiligo  

Vitiligo Clinical Trial

Official title: Study of the Role of Innate Lymphoid Cells and Natural Killer Cells in Immune Activation of Vitiligo

Status Completed

Clinical Trial Summary

The cohort included only major patients with non-segmental vitiligo and no other autoimmune or inflammatory associated diseases (except thyroiditis). Control subjects should have no autoimmune or inflammatory diseases. Patients and controls should not take treatment with corticosteroids or other potentially immunomodulatory therapies. Patients and controls are recruited in the Dermatology Department of the University Hospital of Nice and the Hospital of Fréjus. The investigators have already initiated the collection of tissues and blood from patients and control subjects and we have succeeded in isolating ILCs and NKs from a blood volume of 50ml. We were able to sort the ILC subpopulations. Early data suggest an increase in Natural Killer (NK) and Innate Lymphoïdes Cells 1 (ILC1) in the blood of vitiligo patients compared to control subjects. The investigators also managed to extract the melanocytes from the skin biopsies of the first patients and control subjects.

Clinical Trial Description

The investigators want study the presence and type of ILC and NK in the blood and skin of vitiligo patients compared to control subjects. ;

Related Conditions & MeSH terms

• Vitiligo

• NCT number: NCT03859518
• Study type: Observational
• Source: Centre Hospitalier Universitaire de Nice
• Status: Completed
• Start date: July 2016
• Completion date: December 2019